We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+21.1%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow
% of AUM
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
DexCom
DXCM
$28.4B
| – | – |
-148,000
| Closed | -$17.2M |
|
102
Geron
GERN
$949M
| – | – |
-2,128,000
| Closed | -$4.62M |
|
103
Icon
ICLR
$13B
| – | – |
-142,900
| Closed | -$30.5M |
|
|
104
Merck
MRK
$324B
| – | – |
-600,000
| Closed | -$63.8M |
|
105
Praxis Precision Medicines
PRAX
$8.98B
| – | – |
-285,447
| Closed | -$3.46M |
|
|
RNAM
106
DELISTED
Avidity Biosciences
RNAM
| – | – |
-1,265,545
| Closed | -$19.4M |
|
|
SGMO
107
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| – | – |
-2,470,000
| Closed | -$4.35M |
|
108
Twist Bioscience
TWST
$5.32B
| – | – |
-819,000
| Closed | -$12.4M |
|
|
KNTE
109
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| – | – |
-1,160,000
| Closed | -$7.25M |
|
|
CYT
110
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| – | – |
-1,764,100
| Closed | -$3.21M |
|
|
REUN
111
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
| – | – |
-151,098
| Closed | -$104K |
|
|
ISEE
112
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-1,869,200
| Closed | -$45.5M |
|
|
BLU
113
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-4,553,577
| Closed | -$32.8M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.